Bill's Feed
Apr 24, 2013

Thermo Fisher profit tops Street view as Life awaits

April 24 (Reuters) – Laboratory equipment maker Thermo
Fisher Scientific Inc, which this month agreed to
acquire Life Technologies Inc for more than $13
billion, on Wednesday reported a higher-than-expected
first-quarter profit, helped by a 10 percent rise in specialty
diagnostics sales.

Excluding one-time items, Thermo Fisher posted earnings of
$1.37 per share, topping analysts average expectations by 8
cents, according to Thomson Reuters I/B/E/S.

Apr 23, 2013

Amgen first quarter sales disappoint, shares fall

April 23 (Reuters) – Amgen Inc on Tuesday reported
first-quarter sales that fell short of Wall Street expectations
for most of its biggest-selling medicines, and its shares fell
more than 6 percent.

Revenue for the quarter rose 5 percent to $4.24 billion, but
was shy of Wall Street expectations of $4.37 billion.

Apr 23, 2013

AbbVie hepatitis C drugs knock out virus at eight weeks

By Ransdell Pierson and Bill Berkrot

(Reuters) – A combination of five oral drugs being tested by AbbVie Inc cured at least 88 percent of new patients with hepatitis C after only eight weeks of treatment, without raising significant safety issues, researchers said on Tuesday.

The latest findings from an ongoing trial sponsored by AbbVie, called Aviator, also showed that 96 percent of patients taking the five medicines for 12 weeks eliminated the virus, as assessed by blood tests 24 weeks after they stopped treatment.

Apr 23, 2013

Bristol-Myers oral hepatitis C regimen looks competitive: study

By Bill Berkrot

(Reuters) – A combination of three experimental Bristol-Myers Squibb hepatitis C drugs appeared to be highly effective, according to data from a mid-stage clinical trial, keeping the company in the race for developing an all-oral treatment regimen for the serious liver disease.

The combination therapy, which involves three direct acting antiviral drugs that each attack different targets needed for replication of the hepatitis virus, achieved cure rates as high as 94 percent when given for either 12 weeks or 24 weeks, according to results of the small study.

Apr 22, 2013

Analysis: Ahead of reform, medical care slowdown hits companies

NEW YORK (Reuters) – As the clock ticks down to the start of a U.S. healthcare overhaul, companies from device makers to hospital chains have been surprised to see Americans make even fewer trips to the doctor’s office.

Use of non-emergency medical services has been weak for several years in the wake of a deep recession, high joblessness and the steadily rising cost of care.

Apr 22, 2013

Analysis – Ahead of reform, medical care slowdown hits U.S. companies

NEW YORK (Reuters) – As the clock ticks down to the start of a U.S. healthcare overhaul, companies from device makers to hospital chains have been surprised to see Americans make even fewer trips to the doctor’s office.

Use of non-emergency medical services has been weak for several years in the wake of a deep recession, high joblessness and the steadily rising cost of care.

Apr 22, 2013

Ahead of reform, medical care slowdown hits US companies

NEW YORK, April 22 (Reuters) – As the clock ticks down to
the start of a U.S. healthcare overhaul, companies from device
makers to hospital chains have been surprised to see Americans
make even fewer trips to the doctor’s office.

Use of non-emergency medical services has been weak for
several years in the wake of a deep recession, high joblessness
and the steadily rising cost of care.

Apr 18, 2013

Intuitive Surgical narrows 2013 forecast, shares fall

April 18 (Reuters) – Intuitive Surgical Inc on
Thursday narrowed its 2013 forecasts for growth of revenue and
procedures using its da Vinci surgical robots rather than
raising them as it often does when reporting quarterly results,
and its shares fell.

Intuitive said it expects 2013 procedure growth to come in
at the lower end of its previous forecast of 20 percent to 23
percent and said it sees revenue growth coming in at the higher
end of its initial view of 16 percent to 19 percent.

Apr 15, 2013

Thermo Fisher to buy Life Tech for $13.6 billion

April 15 (Reuters) – Thermo Fisher Scientific Inc on
Monday agreed to buy Life Technologies Corp for $13.6
billion in a deal that would make it one of the top companies in
the hot field of genetic testing.

The pact values Life Tech at $76 per share, a 12 percent
premium, and is one of the year’s biggest corporate takeovers.

Apr 9, 2013

Roche immune therapy cancer drug shows promise in early study

April 9 (Reuters) – An experimental drug that spurs the
immune system to fight cancer appeared to be safe and
demonstrated anti-tumor activity against a variety of cancers in
a small early stage study, researchers said on Tuesday.

The drug, called MPDL320A, was discovered and is being
developed by Roche’s Genentech unit. The Phase 1 trial
of the drug in 30 patients with advanced cancer was designed as
a dose escalation study to test for toxicity at higher doses.

    • About Bill

      "Based in New York, I primarily cover the pharmaceutical and biotechnology sectors as well as other publicly traded companies involved in health care. Previously covered a wide range of sports for Reuters."
    • Follow Bill